Technology
Health
Biotechnology

NuCana

$9.78
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.20 (2.09%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell NuCana and other stocks, options, ETFs, and crypto commission-free!

About NCNA

NuCana Plc engages in the development of technology platform for the treatment of patients with cancer. Its Protide technology is consists of acelarin, NUC-3373, and NUC-7738. Read More The company was founded by Hugh S. Griffith and Christopher B. Wood on January 28, 1997 and is headquartered in Edinburgh, the United Kingdom.

Employees
24
Headquarters
Edinburgh, Midlothian
Founded
1997
Market Cap
304.03M
Price-Earnings Ratio
Dividend Yield
Average Volume
52.98K
High Today
$9.74
Low Today
$9.50
Open Price
$9.59
Volume
5.28K
52 Week High
$30.10
52 Week Low
$9.03

Collections

Technology
Health
Biotechnology
Cancer Prevention
2017 IPO
UK
Europe

NCNA News

Yahoo FinanceJun 13

NuCana's Biliary Tract Cancer Candidate Gets Orphan Drug Tag

50

NCNA Earnings

-$21.52
-$14.36
-$7.21
-$0.05
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 27, After Hours

More NCNA News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.